清晨好,您是今天最早来到科研通的研友!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您科研之路漫漫前行!

P0011 Functional Advantage of Afimkibart’s Preference for Trimeric TL1A in Blocking Active TL1A Signaling

细胞生物学 先天免疫系统 效应器 免疫系统 肿瘤坏死因子α 信号转导 T细胞 HEK 293细胞 受体 抗原提呈细胞 免疫学 表面等离子共振 单克隆抗体 配体(生物化学) 医学 趋化因子 细胞培养 细胞 生物 化学 体外 共刺激 发病机制 巨噬细胞 抗体 炎症性肠病 外周血单个核细胞 细胞毒性T细胞 重组DNA 促炎细胞因子
作者
F Fuh,E Varfolomeev,A Nguyen,A Oh,G Merana,Xiao Tao,Karen L. Lasch,M Neighbors,V Mohanan,D Vucic
出处
期刊:Journal of Crohn's and Colitis [Oxford University Press]
卷期号:20 (Supplement_1) 被引量:1
标识
DOI:10.1093/ecco-jcc/jjaf231.192
摘要

Abstract Background Tumor necrosis factor-like ligand 1A (TL1A) is a member of the TNF superfamily implicated in the pathogenesis of inflammatory bowel disease (IBD) as a key amplifier of effector immune cell function. TL1A is expressed by multiple immune cell types, including macrophages, dendritic cells, and exists as either a membrane-bound or cleaved soluble form. TL1A signals through death receptor 3 (DR3), activating the NF-κB pathway in effector T cells and innate lymphoid cells (ILCs). TL1A can exist in trimeric or monomeric form. Afimkibart is a fully human monoclonal antibody that has demonstrated clinical benefit in Phase 2 studies and selectively neutralizes trimeric, functionally active TL1A. In contrast, monomeric TL1A has been described, but its physiological role needs to be further investigated. Methods Recombinant monomeric and trimeric TL1A proteins were evaluated for binding to afimkibart using surface plasmon resonance (SPR) and for functional activity in primary immune cells and cell lines by measuring NF-κB signaling and interferon-gamma (IFNγ) production. Results Trimeric recombinant human TL1A (rhTL1A) robustly induced NF-κB activation in peripheral T lymphocytes and, in the presence of IL12 and IL18 co-stimulation, significantly enhanced IFN-γ production in human PBMCs. Both readouts were potently inhibited by afimkibart. Monomeric rhTL1A, even at high concentrations (>100 ng/mL), elicited only minimal NF-κB activation and a marginal IFN-γ response. Importantly, afimkibart does not bind monomeric TL1A, confirming it selectively recognizes the active, trimeric species. This selectivity prevents afimkibart from being sequestered by any non-signaling TL1A monomers, thereby avoiding the target “sink” effects that impact in vitro potency for antibodies binding both monomeric and trimeric TL1A. Afimkibart also effectively blocked both soluble and membrane-bound forms of endogenous active TL1A. Conclusion Afimkibart is a potent and selective antagonist of the functionally active, trimeric TL1A, efficiently blocking TL1A-induced NF-κB signaling and IFN-γ production. The inability of afimkibart to bind monomeric TL1A may represent a distinct pharmacologic advantage by ensuring selective targeting of the signaling-competent TL1A form for optimal pharmacokinetic and pharmacodynamic properties. This functional specificity underpins the therapeutic potential of afimkibart in TL1A-driven diseases such as IBD. Conflict of interest: Fuh, Franklin: Employment and stock/stock options at Genentech Inc. Varfolomeev, Eugene: I am an employee and shareholder of Genentech-Roche. Nguyen, Allen: I am employed by Genentech, Inc., a subsidiary of Roche, Inc. I own Roche shares/stock. Oh, Angela: I am an employee of Genentech, Inc. and have Roche stock. Merana, Geil: I am an employee and shareholder of Genentech-Roche. Tao, Xiao: I am a full-time employee of Genentech, Inc. (a Roche subsidiary) where the data is sourced/generated. And I am a Roche stock owner. Lasch, Karen: Employed by Roche/Genentech with stock or other ownership interests in Roche/Genentech. Dr. Neighbors, Maggie: I am a full-time employee of Genentech, Inc., a wholly owned subsidiary of Roche, and receive Roche stock/options. Mohanan, Vishnu: Full time employee of Genentech/Roche and holds Roche shares. Vucic, Domagoj: I am an employee and shareholder of Genentech-Roche.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
称心怜菡完成签到,获得积分10
1秒前
水中央完成签到 ,获得积分10
3秒前
乐正怡完成签到 ,获得积分0
9秒前
naczx完成签到,获得积分0
9秒前
14秒前
16秒前
21秒前
youyuzhuanjia完成签到,获得积分20
28秒前
痴情的皮皮虾完成签到,获得积分10
29秒前
31秒前
文静飞松完成签到,获得积分10
31秒前
youyuzhuanjia发布了新的文献求助10
32秒前
syvshc的应助被parantal采纳,获得10
39秒前
45秒前
hh完成签到 ,获得积分10
46秒前
49秒前
zenith968完成签到,获得积分10
52秒前
洁净友蕊完成签到,获得积分10
52秒前
53秒前
58秒前
文艺夜白完成签到,获得积分10
1分钟前
靓丽花瓣完成签到,获得积分10
1分钟前
1分钟前
黑质完成签到,获得积分10
1分钟前
1分钟前
1分钟前
小小虾完成签到 ,获得积分10
1分钟前
柔弱藏花完成签到,获得积分10
1分钟前
2分钟前
2分钟前
gushaohua007完成签到 ,获得积分10
2分钟前
小g完成签到 ,获得积分10
2分钟前
yb完成签到,获得积分10
2分钟前
2分钟前
彩色的勒完成签到,获得积分10
2分钟前
美好远航完成签到,获得积分10
2分钟前
weibo完成签到,获得积分10
2分钟前
哈哈哈哈哈完成签到,获得积分10
2分钟前
2分钟前
共享精神的应助被科研通管家采纳,获得10
2分钟前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
plantTFDB 508
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8173225
求助须知:如何正确求助?哪些是违规求助? 9565575
关于积分的说明 21780525
捐赠科研通 7767395
什么是DOI,文献DOI怎么找? 3431542
关于科研通互助平台的介绍 2555764
邀请新用户注册赠送积分活动 2476697